| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1018: Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis |
|
Medicine details |
|
| Medicine name | fedratinib (Inrebic®) |
| Formulation | 100 mg hard capsule |
| Reference number | 1488 |
| Indication | Treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are JAK inhibitor naïve or who have been treated with ruxolitinib |
| Company | Celgene Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/05/2021 |
| NICE guidance | TA1018: Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis |